What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The National Development and Reform Commission, China's state planning agency, charged consumer goods company Unilever a fine of RMB 2 million ($310,000) for price manipulation May 6. The NDRC action was taken in an effort to suppress consumer inflation, but a key takeaway, according to experts, is that multinational companies should be cautious about how they communicate pricing information to the market or they may find themselves in violation of China's Price Law, Anti-Monopoly Law or even foreign antitrust and anti-bribery rules
You may also be interested in...
New Framework Anticipates More Anti-monopoly Cases In China
China's Supreme People's Court released guidance that makes it easier for civilians to file anti-monopoly cases against pharmaceutical companies and other industries.
China’s NDRC Issues Anti-Monopoly Law's Priciest Fine Ever On Two Chinese Firms Manipulating Raw Ingredient Sales
Is NDRC sending a message that the pharma industry is too important to be left to industry regulation alone?
China Tries To Curb Rising TCM Ingredient Prices, But Hikes Persist
HONG KONG - The prices of basic ingredients in traditional Chinese medicines used across China and various other countries in Asia are rising rapidly. Authorities in China have stepped in to control prices but a combination of factors, including the potential profits available in trading TCM ingredients and the growing popularity of TCM globally are driving prices upwards